In its latest quarter ended March 31, 2026, Axsome Therapeutics reported continued commercialization progress for its three FDA-approved CNS therapies—AUVELITY, SUNOSI, and SYMBRAVO—with revenues driven by product sales though overall financial profitability remains elusive. The company maintains solid liquidity backed by $305 million in cash against $120 million in term debt, supporting expansive R&D efforts and pipeline advancement including recently acquired assets with promising CNS indications. Axsome's business model hinges on launching differentiated CNS products with novel mechanisms that address unmet clinical needs, but faces risks from regulatory uncertainties, competitive pressures, and the need for continued financing to achieve sustainable profitability.